HER2 testing: Current status and future directions

Edith A. Perez, Javier Cortés, Ana Maria Gonzalez-Angulo, John M.S. Bartlett

Research output: Contribution to journalReview article

81 Scopus citations

Abstract

Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy. However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient groups who would derive a clear clinical benefit. ASCO/CAP are currently reviewing their guidelines to further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status.

Original languageEnglish (US)
Pages (from-to)276-284
Number of pages9
JournalCancer Treatment Reviews
Volume40
Issue number2
DOIs
StatePublished - Mar 1 2014

Keywords

  • American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
  • Human epidermal growth factor receptor 2 (HER2) testing
  • Immunohistochemistry
  • In situ hybridization
  • Variability

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'HER2 testing: Current status and future directions'. Together they form a unique fingerprint.

  • Cite this

    Perez, E. A., Cortés, J., Gonzalez-Angulo, A. M., & Bartlett, J. M. S. (2014). HER2 testing: Current status and future directions. Cancer Treatment Reviews, 40(2), 276-284. https://doi.org/10.1016/j.ctrv.2013.09.001